Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| C412007-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $39.90 | |
| C412007-1mg | 1mg | In stock | $159.90 | |
| C412007-5mg | 5mg | In stock | $664.90 | |
| C412007-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,196.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Camrelizumab (anti-PD-1), for Flow,ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR) various applications, specific to PDCD1, >95%, high purity, Human IgG4SP |
|---|---|
| Synonyms | SHR-1210; CD279 antigen; CD279; hPD-1; PD1; PD-1; PD1hPD-l; PDCD1; programmed cell death 1; programmed cell death protein 1; Protein PD-1; SLEB2; CD279 antibody; CD279 antigen antibody; hPD 1 antibody; hPD l antibody; hPD-1 antibody; hSLE1 antibody; PD 1 |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | PDCD1 |
| Application | Flow,ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | ANTAGONIST |
| Mechanism of action | ANTAGONIST of Programmed cell death protein 1 antagonist |
| Product Description | Information Camrelizumab is a potent anti-PD-1 /PD-L1 active molecule that can be used in cancer research, including non-small cell lung cancer, esophageal squamous cell carcinoma, Hodgkin lymphoma, and advanced liver cancer. Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG4SP |
| Light Chain Type | kappa |
| SDS-PAGE | 26.6 kDa (Light Chain) & 52.7 kDa (Heavy Chain), under reducing conditions; 177.2 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1798286-48-2 |
Camrelizumab (anti-PD-1) (C412007) - Flow Cytometry
Flow Cytometry analysis of 5μg/mL PHA stimulated 3 days human peripheral blood lymphocytes labelling PD-1 (red) with Camrelizumab (anti-PD-1) (C412007) conjugated with biotin and detected with SA-PE (rp156250). Blue - Isotype control, human IgG (Ab170213) conjugated with biotin. Black - Unlabelled control, cells without incubation with primary antibody.
Camrelizumab (anti-PD-1) (C412007) - Flow Cytometry
Flow Cytometry analysis of MOLT-4 cells labelling PD-1 (red) with Camrelizumab (anti-PD-1) (C412007). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Camrelizumab (anti-PD-1) (C412007) - SEC
The purity of Camrelizumab (anti-PD-1) (C412007) is more than 95% verified by HPLC.
Camrelizumab (anti-PD-1) (C412007) - ELISA
Immobilized TARGET at 2 μg/mL can bind Camrelizumab (anti-PD-1) (C412007) with the EC₅₀ of 8.25 ng/mL.
Camrelizumab (anti-PD-1) (C412007) - ELISA
Immobilized Recombinant Human PD-1 Protein (rp176241) at 1.0 μg/mL can bind Camrelizumab (anti-PD-1) (C412007) with the EC50 of 10.39 ng/mL.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| IMGT/mAb-DB | 659 |
|---|---|
| Reactome Reaction | R-HSA-9679421 |
| Reactome Drug | R-ALL-9679471 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0607389 | Certificate of Analysis | Jun 26, 2024 | C412007 |
| ZJ23F1202075 | Certificate of Analysis | Dec 20, 2023 | C412007 |
| ZJ23F1202074 | Certificate of Analysis | Dec 20, 2023 | C412007 |
| 1. Markham A, Keam SJ. (2019) Camrelizumab: First Global Approval.. Drugs, 79 (12): (1355-1361). [PMID:31313098] |
| 2. Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K et al.. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs.. Nat Genet, 36 (1): (40-5). [PMID:14702039] |
| 3. Kline J, Gajewski TF. (2010) Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.. Curr Opin Investig Drugs, 11 (12): (1354-9). [PMID:21154117] |
| 4. Hall RD, Gray JE, Chiappori AA. (2013) Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.. Cancer Control, 20 (1): (22-31). [PMID:23302904] |
| 5. Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q et al.. (2017) Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.. Mol Cancer Ther, 16 (5): (861-870). [PMID:28265006] |
| 6. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. (2015) Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.. Structure, 23 (12): (2341-2348). [PMID:26602187] |
| 7. L R Finger,J Pu,R Wasserman,R Vibhakar,E Louie,R R Hardy,P D Burrows,L G Billips. (1997-10-23) The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors.. Gene, 197 ((1-2)): (177-187). [PMID:9332365] |
| 8. Cheng B, Ren Y, Niu X, Wang W, Wang S, Tu Y, Liu S, Wang J, Yang D, Liao G, Chen J.. (2020) Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.. J Med Chem, 63 (15): (8338-8358). [PMID:32667799] |
| 9. Shinohara, T T, Taniwaki, M M, Ishida, Y Y, Kawaichi, M M and Honjo, T T.. (1994) Structure and chromosomal localization of the human PD-1 gene (PDCD1).. Genomics, [PMID:7851902] |
| 10. Prokunina, Ludmila L and 23 more authors.. (2002) A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans.. Nature genetics, [PMID:12402038] |
| 11. Fife, Brian T BT and Pauken, Kristen E KE.. (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance.. Annals of the New York Academy of Sciences, [PMID:21276005] |
| 12. Topalian, Suzanne L SL and 29 more authors.. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.. The New England journal of medicine, (28): [PMID:22658127] |
| 13. Cheng, Xiaoxiao X and 18 more authors.. (2013) Structure and interactions of the human programmed cell death 1 receptor.. The Journal of biological chemistry, (26): [PMID:23417675] |
| 14. Robert, Caroline C and 27 more authors.. (2015) Nivolumab in previously untreated melanoma without BRAF mutation.. The New England journal of medicine, (22): [PMID:25399552] |
| 15. McDermott, J J and Jimeno, A A.. (2015) Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.. Drugs of today (Barcelona, Spain : 1998), [PMID:25685857] |
| 16. Na, Zhenkun and 6 more authors.. (2017) Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab.. Cell research, [PMID:27325296] |
| 17. Pascolutti, Roberta R and 6 more authors.. (2016) Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant.. Structure (London, England : 1993), (4): [PMID:27618663] |
| 18. Horita, Shoichiro S and 5 more authors.. (2016) High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.. Scientific reports, (13): [PMID:27734966] |
| 19. Tan, Shuguang S and 15 more authors.. (2017) An unexpected N-terminal loop in PD-1 dominates binding by nivolumab.. Nature communications, (6): [PMID:28165004] |
| 20. Berger, Kristin Nicole KN and Pu, Jeffrey Jiayu JJ.. (2018) PD-1 pathway and its clinical application: A 20year journey after discovery of the complete human PD-1 gene.. Gene, (5): [PMID:28951311] |
